- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04545450
Effects of Testosterone Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolism in Transmen (DUTMUSCLE-20)
A Randomized Double-blind Placebo-controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolic Profile in Transmen
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Transmen who have undergone gender-affirming surgery require long-lasting treatments with androgens to maintain male phenotypic characteristics and to preserve their health. In this population the effects on muscle and the relative role of testosterone and its metabolite dihydrotestosterone (DHT) on the skeletal muscle are still largely unknown.
In this pilot study, we evaluated the effects of testosterone and DHT on muscle strength, body composition, metabolism. Also cutaneous androgenic effects such as acne and androgenetic alopecia were evaluated.
DESIGN
For this purpose, in this randomized, double-blind placebo-controlled pilot trial we treated variectomized transmen for 54 weeks with:
- Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill (TU+PL)
- TU 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day (TU+DUT).
Prospective, phase III, randomized study design was used.
Subjects were seen every 12 weeks for safety monitoring that included evaluation of hematocrit, transaminases, alkaline phosphatases and bilirubin, creatinine, urea and serum electrolyte as potassium and sodium.
Baseline and week-54 evaluations included the following measurements:
blood drawings for measurements of: hormonal profile (serum testosterone, estradiol, luteinizing hormone and follicle-stimulating hormone, prolactin, sex hormone binding globulin, and thyroid stimulating hormone), haematocrit (Ht) and haemoglobin (Hb), glucidic and lipidic profile (fasting glucose, fasting insulin, total cholesterol, high- and low-density lipoproteins, and triglycerides), hepatic function (aspartate and alanine aminotransferases) and bone related markers (osteocalcin, parathyroid hormone, bone alkaline phosphatase and 25-hydroxyvitamin, 24h urinary excretion of calcium, potassium, magnesium and creatinine).
anthropometry: weight, measures DEXA for bone mass determination and body composition Isokinetic knee extension and flexion peak torque (PT-IKE and PT-IKF) Handgrip strength evalutation of the psychological profile with the brief Profile of Mood State (POMS) sexual life satisfaction evalutation with a Visual Analogue General Satisfaction Scale (VAS) physical examination: inspection of external genitalia (clitorides) and a visit to detect appearance of acne and gynecomastia
During the treatment phase all injections will be administered by the investigator or co-investigators for the entire study. Fasting (10 hours) blood samples will be taken (immediately before giving the injections) every time subjects come for injections (week 0, 6, 18, 30 and 42) and at the end of the treatment phase.
In the sexual and behavior questionnaire the subjects will judge their sexual activity and behavior in the period between visits. The subjects have the possibility to making additional comments about important events and disturbances.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy transmen
- Previous bilateral gonadectomy during sex reassigning surgery
- Body Mass Index (BMI) between 20 and 29 kg/m²; (body weight in kilograms divided by body height in meters squared)
- Clinical examination without pathological findings relevant to the study
- No concomitant use of drugs known to affect the hypothalamic-pituitary-ovarian axis
- Written Consent Form
- High probability of a good compliance and termination of the study
Exclusion Criteria:
- Participation in another clinical trial within the 30 days preceding the first administration
- Simultaneous participation in another clinical trial
- Subjects institutionalized or imprisoned by order of the court
- Subject who compete in sports
- Subjects reporting desire to perform regular physical exercises for the duration of the study
- Serious organic or psychic disease suspected from history and/or clinical examination
- Diseases (especially tumors) that might represent an actual contraindication for testosterone
- Past or present history of thrombotic or embolic diseases
- Arterial hypertension
- Diabetes mellitus
- Acute or chronic hepatic diseases
- Manifest renal diseases with renal dysfunction
- Severe internal diseases
- Biochemical and/or hematological laboratory values beyond normal ranges unless the Investigator confirms that the deviations are of no clinical relevance
- Any indication of chronic use of drugs, alcohol, opiates or recreational drugs
- Use of any drug known to affect biotransformation of testosterone and/or progestin, e.g. chlorcycline, phenobarbital, phenylbutazone, aminophenazone within the 30 days preceding the first administration of the test medication and during the study
- Use of oral anticoagulatory drugs within the 30 days preceding the first administration of the test medication and during the study
- Any oral or transdermal hormone medication within the 12 weeks preceding the first administration and during the study
- Probability of poor compliance and termination of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Testosterone Undecanoate plus dutasteride
Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day
|
Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
|
Placebo Comparator: Testosterone Undecanoate plus placebo
Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill
|
Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in isokinetic knee extension and flexion peak torque (PT-IKE and PT-IKF)
Time Frame: At baseline and after 54 weeks of treatment
|
Isokinetic peak torques were determined using isokinetic dynamometry (Biodex System 4 Pro, Medical Systems, Shirley, NY) at all four time points.
|
At baseline and after 54 weeks of treatment
|
Change in handgrip strength
Time Frame: At baseline and after 54 weeks of treatment
|
Three trials of three sets of maximal isometric handgrip on a mechanical dynamometer (model Grip-A, Takei Physical Fitness Test TKK 5001, Japan), alternately with the dominant and non-dominant hand, with a three minute rest between each trial
|
At baseline and after 54 weeks of treatment
|
Change in body composition
Time Frame: At baseline and after 54 weeks of treatment
|
Dual-energy X-ray absorptiometry was performed using the Hologic 49159 densitometer and standard QDR body composition software (Model QDR4500W, Software Level 11.2, Hologic Spine; Hologic, Bedford, MA) for the measurement of body fat and lean mass
|
At baseline and after 54 weeks of treatment
|
Change in bone mineral density
Time Frame: At baseline and after 54 weeks of treatment
|
Dual-energy X-ray absorptiometry was performed using the Hologic 49159 densitometer and standard QDR body composition software (Model QDR4500W, Software Level 11.2, Hologic Spine; Hologic, Bedford, MA) for the evaluation of bone mineral density at lumbar and femoral site
|
At baseline and after 54 weeks of treatment
|
Change in anthropometric assessment: BMI
Time Frame: At baseline and after 54 weeks of treatment
|
weight, stature will be combined to report the BMI (kg/m^2)
|
At baseline and after 54 weeks of treatment
|
Change in anthropometric assessment: waist-to-hip ratio
Time Frame: At baseline and after 54 weeks of treatment
|
Waist and hip circumferences will be combined to report the waist-to-hip ratio (WHR)
|
At baseline and after 54 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in psychological profile with the brief Profile of Mood State (POMS)
Time Frame: At baseline and after 54 weeks of treatment
|
The POMS is a self-reporting questionnaire consisting of 30 items in six categories: tension-anxiety, depression, anger-hostility, vigor, fatigue and confusion, which are scored from 1-4 according to severity
|
At baseline and after 54 weeks of treatment
|
Change in the satisfaction with their sexual life
Time Frame: At baseline and after 54 weeks of treatment
|
using a Visual Analogue General Satisfaction Scale (VAS).
A VAS for satisfaction is a horizontal line of 10-cm long.
At the start and finish there are two descriptors representing extremes of satisfaction (i.e.
no satisfaction and extreme satisfaction).
Subjects respond to the question 'Are you satisfied with your sexual life now?' and rate their satisfaction by making a vertical mark on the 100-mm line.
The measurement in millimeters is converted to the same number of points ranging from zero to 10 points.
|
At baseline and after 54 weeks of treatment
|
Change in in the bone metabolism: osteocalcin
Time Frame: At baseline and after 54 weeks of treatment
|
Evaluation of serum osteocalcin (OC) change
|
At baseline and after 54 weeks of treatment
|
Change in in the bone metabolism: parathyroid hormone
Time Frame: At baseline and after 54 weeks of treatment
|
Evaluation of serum parathyroid hormone (PTH) changes
|
At baseline and after 54 weeks of treatment
|
Change in in the bone metabolism: bone alkaline phosphatase
Time Frame: At baseline and after 54 weeks of treatment
|
Evaluation of serum bone alkaline phosphatase (BAP) changes
|
At baseline and after 54 weeks of treatment
|
Change in in the bone metabolism: urinary excretion of electrolites
Time Frame: At baseline and after 54 weeks of treatment
|
Changes in the 24h urinary excretion of electrolites
|
At baseline and after 54 weeks of treatment
|
Change in in the insulin resistance
Time Frame: At baseline and after 54 weeks of treatment
|
Change in the HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)
|
At baseline and after 54 weeks of treatment
|
Change in the lipid profile
Time Frame: At baseline and after 54 weeks of treatment
|
Changes in cholesterol (Tot Chol and high- and low-density lipoproteins) levels
|
At baseline and after 54 weeks of treatment
|
Change in the lipid profile
Time Frame: At baseline and after 54 weeks of treatment
|
Changes in triglycerides levels
|
At baseline and after 54 weeks of treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Androgens
- 5-alpha Reductase Inhibitors
- Anabolic Agents
- Testosterone
- Dutasteride
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- DUTMUSCLE-20
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadism
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Shanghai Jiao Tong University School of MedicineUnknownIdiopathic Hypogonadotropic Hypogonadism
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Clarus Therapeutics, Inc.CompletedMale Hypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.CompletedHypogonadotropic Hypogonadism | Primary HypogonadismUnited States
-
Endo PharmaceuticalsCompletedHypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Fudan UniversityRecruitingIdiopathic Hypogonadotropic Hypogonadism | Luteal Phase Support | Luteal Phase DeficiencyChina
-
Repros Therapeutics Inc.CompletedObesity | Acquired Hypogonadotropic HypogonadismUnited States
-
Massachusetts General HospitalRecruiting
-
Mereo BioPharmaCompleted
Clinical Trials on dutasteride 5 mg/day
-
Ferring PharmaceuticalsTerminatedChronic Idiopathic ConstipationSweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
-
Chinese PLA General HospitalCompletedStem Cell Transplant Complications | aGVHDChina
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingGranulomatosis With PolyangiitisUnited States, Canada
-
Dr. J. Curtis NickelUniversity of California, Los Angeles; The Cleveland ClinicTerminatedBenign Prostatic Hyperplasia | Chronic ProstatitisCanada
-
Merck Sharp & Dohme LLCTerminated
-
ReveraGen BioPharma, Inc.National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedDuchenne Muscular DystrophyUnited States, Canada, United Kingdom, Sweden, Australia, Israel
-
ReveraGen BioPharma, Inc.University of Pittsburgh; Cooperative International Neuromuscular Research...CompletedDuchenne Muscular DystrophyUnited States, Canada, United Kingdom, Sweden, Australia, Israel
-
Yuyu Pharma, Inc.CompletedBenign Prostatic HyperplasiaKorea, Republic of
-
Ayesha De CostaBoston Children's Hospital; Muhimbili University of Health and Allied Sciences and other collaboratorsCompleted
-
Turku University HospitalRecruitingProstatic Hyperplasia | Prostate CancerFinland